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Abstract
Background: This article provides a description of the rationale, design, and methods of a multisite clinical trial
which evaluates the potential benefits of an evidence-based psychosocial treatment, STAIR Narrative Therapy,
among women with posttraumatic stress disorder (PTSD) related to interpersonal violence who are seeking services
in public sector community mental health clinics. This is the first large multisite trial of an evidence-based treatment
for PTSD provided in the context of community settings that are dedicated to the treatment of poverty-level patient
populations.
Methods: The study is enrolling 352 participants in a minimum of 4 community clinics. Participants are randomized
into either STAIR Narrative Therapy or Treatment As Usual (TAU). Primary outcomes are PTSD, emotion management
and interpersonal problems. The study will allow a flexible application of the protocol determined by patient need and
preferences. Secondary analyses will assess the relationship of outcomes to different patterns of treatment
implementation for different levels of baseline symptom severity.
Discussion: The article discusses the rationale and study issues related to the use of a flexible delivery of a protocol
treatment and of the selection of treatment as it is actually practiced in the community as the comparator.
Trial registration: Clinicaltrials.gov identifier: NCT01488539.
Keywords: PTSD, Community mental health clinics, Women’s health, Flexible service delivery
Background
Public sector mental health services are the dispropor-
tionate recipients of patients with trauma histories and,
not surprisingly, such settings report high rates of post-
traumatic stress disorder (PTSD) in their patient popula-
tion. Exposure to traumatic stressors is reported by 62%
to 98% of public sector patient samples and prevalence
rates of PTSD range from 19% to 43% [1-3]. PTSD tends
to occur more frequently in women than in men, and is
most commonly related to multiple instances of inter-
personal violence including those reaching back to child-
hood experiences of sexual and physical abuse [1]. PTSD
related to interpersonal violence is particularly pernicious
as it is associated with significant psychiatric co-
morbidity, high rates of suicide attempts, abuse of alcohol
and drugs, and chronic interpersonal and relationship dif-
ficulties [4]. At least 40 single-site randomized trials of
cognitive behavioral therapy for PTSD have been con-
ducted [5,6], and these trials have resulted in the identifi-
cation of several efficacious therapies. However, to date,
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large community settings has been limited to military
populations and military clinics.
Given the pervasive presence of trauma histories and
PTSD in patients seeking treatment in public sector
mental health settings, there is great need to evaluate
evidence-based treatments in these settings and to dis-
seminate those shown to be effective. In addition, re-
search is needed on processes that facilitate the adoption
and effective use of EBTs in community settings.
This article describes a National Institute of Mental
Health (NIMH) funded study in which the effectiveness of
an evidence-based treatment for women with PTSD related
to interpersonal violence will be assessed and compared to
treatment as usual in low-income community public sector
outpatient clinics. The intervention to be evaluated is
STAIR Narrative Therapy, a two-module, sequential treat-
ment that was specifically developed to treat women with
chronic PTSD, common co-morbid symptoms, and sub-
stantially impaired functioning [7,8]. The first module em-
phasizes skills training in affective and interpersonal
regulation (STAIR) and has the primary goal of improving
daily life functioning, while the second module (Narrative
Therapy) incorporates and focuses on the review and re-
appraisal of trauma memories [9].
The proposed study utilizes a hybrid efficacy/effect-
iveness design [10]. This type of trial focuses on the
evaluation of the benefit of a treatment when applied in
a community service setting under research sampling
and assessment conditions. Its design has features that
maintain internal and construct validity, while the treat-
ment is evaluated under ‘real world’ clinical conditions
that enhance external validity and generalizability. Gener-
alizability features include engagement of sites with eth-
nically and racially diverse populations, few inclusion and
exclusion participant criteria, use of community clinicians,
a flexible approach to treatment application, and clinical
training and supervision consistent with service environ-
ments. Aspects of efficacy designs that are maintained in
the proposed study are: random assignment of patients
into STAIR Narrative Therapy (SNT) or Treatment as
Usual (TAU), use of reliable and standardized diagnosis
assessment measures, and use of a manual to guide the
protocol treatment and relatively intensive quality assur-
ance of diagnostic assessments and of adherence to the
treatment protocol.
The study also incorporates several elements of imple-
mentation science research. Clinicians are encouraged to
use the SNT protocol in a flexible manner within clear
limits, according to the symptoms, needs, and prefer-
ences of the specific patient. We view the incorporation
of clinician-driven decisions regarding application of the
protocol as an important ingredient in facilitating the
use and dissemination of EBTs in the community. We
will conduct exploratory analyses identifying implemen-
tation patterns and their relationship to outcomes for
patients and also examine the influence of therapist and
organizational characteristics likely to impact implemen-
tation. These include, but are not limited to, therapists’
attitudes about the intervention and administrative sup-
port for implementation of the intervention within the
service. The study also introduces web-based technology
as a resource intended to strengthen clinical networks
and maintain use of study materials about which we will
obtain qualitative data from clinicians regarding its per-
ceived value.
This article provides a description of the study design
and reasons for design decisions such the selection of
TAU as a comparator and the use of flexible delivery of
SNT. These choices were intended to increase clinical
realism and the generalizability of findings. However,
they also added to the complexity of the study. The
selection of TAU, which in a multisite study differs from
site to site, requires consideration about how to char-
acterize and assess TAU interventions and analytic tech-
niques that take between-site variability in TAU into
account. Similarly, the use of a flexible delivery of the
test treatment incorporates clinician judgment and sup-
ports patient-centered care, but requires careful consid-
eration about how to define and ensure adherence to the
protocol. The study description below provides an ex-
ample of the issues encountered in hybrid efficacy-
effectiveness clinical trials. We present the rationale for
our decisions and the scientific literature that guided
them.
The study has two aims: (1) to evaluate the effective-
ness of SNT relative to TAU primarily in regards to
PTSD symptom reduction and secondarily in regards to
treatment attendance, attrition, and therapist and patient
satisfaction, and (2) to explore the relationship between
variations in SNT treatment implementation and out-
come relative to baseline severity of illness (for example,
PTSD severity, GAF score). In addition, the study will
obtain qualitative data concerning therapist and staff at-
titudes about contextual variables (for example, adminis-
trative support, clinic resources) including the use of
technology (SNT resource website) that facilitate or im-
pede implementation of the EBT and will explore their
relationship to intervention delivery and outcome. These
data will be collected via interviews conducted at the
midpoint and endpoint of the clinical trial.
Methods
Design
The study design is a randomized controlled trial of
treatment in US public sector mental health outpatient
settings (see Figure 1). A minimum of four sites will par-
ticipate in the study. Within each site, participants will
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ment condition will be implemented by a minimum of
two therapists. Each therapist delivers only one of the in-
terventions. Selection of sites includes demonstration of
ability to recruit a minimum of three study participants
per month based on number of new trauma patients en-
tering the clinic on a yearly basis and on the percent of
such patients with PTSD diagnoses. Other features re-
quired of sites include the presence of Institutional Re-
view Board (IRB) and administrative resources and
infrastructure to provide fiscal management, reporting,
and quality assurance required by the funder, NIMH.
Participants
Participants must be women aged between 18 and
65 years. They must have a primary diagnosis of PTSD
according to DSM-IV criteria [11] with a Clinician Ad-
ministered PTSD Scale (CAPS) score no lower than 40
[12]. The PTSD symptoms must be a result of interper-
sonal violence and participants must have at least one
clear trauma memory.
Exclusion criteria are as follows: substance dependence
and severe substance abuse disorders, current psychotic
symptoms, unmedicated mania or bipolar disorder;
prominent current suicidal or homicidal ideation (a plan
or intent versus a wish) or a suicide attempt within the
past 3 months; self-injurious behaviors in the last
3 months requiring medical attention; cognitive impair-
ment indicated by chart diagnoses or observable cogni-
tive difficulties; and current involvement in a violent
relationship defined as more than casual contact (for ex-
ample, dating or living with an abusive partner). Individ-
uals for whom a co-morbid disorder is identified as of
greater clinical significance than PTSD as defined by the
SCID (for example, severe eating disorder, severe Bor-
derline Personality Disorder) are for clinical and ethical
reasons referred to services that treat these disorders.
Severe BPD is defined as having at least the following
three symptoms in concert: (1) fear of abandonment, (2)
unstable self, and (3) frequent and ongoing self-injurious
or suicidal behavior under stress. Thus, inclusion/exclu-
sion criteria allow individuals with substantial psychiatric
difficulties including: severe depression, moderate sub-
stance dependence, eating disorders, moderate borderline
personality disorder, and history of psychotic disorders or
currently medicated psychotic disorders.
Assessment
Consistent with the plans for flexible application of SNT
and with the variable length of naturally occurring TAU,
treatment duration is free to vary but assessments will
be conducted at fixed intervals [13]. This will allow a
direct comparison of the two treatment conditions, SNT
and TAU, regarding improvement and differential rates
of change over time. Participants will be informed that
the assessments will be conducted on a fixed schedule,
independent of the number of sessions or expected dur-
ation of the therapy. After randomization, assessments
will be conducted according to the following schedule:
during the 28th week, the 36th week, and the 48th week
from randomization, after which the treatment trial will
end for participants in both conditions and referral to
another therapist or clinic will be provided as needed.
The measures and domains are summarized in Table 1.
The primary outcome is PTSD symptom severity as
measured by the CAPS [14] and remission from the dis-
order, defined as no longer meeting the diagnosis of
PTSD and having a CAPS score no greater than 20 [12].
Patient with PTSD Symptoms
N=352
Site 1
N= 88
Site 2
N= 88
Site 3
N= 88
Site 4
N= 88
SNT
N=44
Th1
N=22
Th2
N=22
TAU
N=44
Th1
N=22
Th2
N=22
Th1
N=22
Th2
N=22
SNT
N=44
TAU
N=44
SNT
N=44
TAU
N=44
SNT
N=44
TAU
N=44
28 weeks post randomization
N= 299
36 weeks post randomization
N= 284
48 weeks post randomization
N= 270
Enrollment
Randomization
Follow-Up
Th1
N=22
Th2
N=22
Th1
N=22
Th2
N=22
Th1
N=22
Th2
N=22
Th1
N=22
Th2
N=22
Th1
N=22
Th2
N=22
Figure 1 Diagram of participant flow.
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as measured by the Difficulties in Emotion Regulation
Scales (DERS; [15]), interpersonal problems as measured
by the Inventory of Interpersonal Problems (IIP; [16]),
and global functioning as measured by the Global As-
sessment of Functioning (GAF) from the SCID [17].
Several additional assessment measures are obtained
at baseline to evaluate overall mental and physical
health. These include the Brief Symptom Inventory (BSI)
[18] and the Trauma Symptom Inventory dissociation
subscale (TSI) [19], the Structured Clinical Interview for
Diagnosis (SCID) for all Axis I disorders [17], and the
SCID II screen to identify probable Axis II disorders
[20]. Current health status is measured by the SF-36 [21]
and health service utilization by the Health Service
Utilization Form (HSUF) (Berman M, Franklin M, Cox J,
Foa E, Miller S: The Quality Of Life Self-Report Instru-
ment, unpublished). Additional secondary measures focus-
ing on more complex aspects of PTSD included at the
major assessment points for exploratory purposes are
the Complex Trauma Symptoms Questionnaire (CTSQ)
[Mendelsohn M, Herman JL, Cloitre M, Henne-Hasse C,
Jackson C, Kaslow NJ, Lanius R: The Complex Trauma
Symptom Questionnaire, Unpublished manuscript], the
Affective Experience Questionnaire (AEQ) [Frewen P: The
Affective Experience Questionnaire, Unpublished manu-
script], the Self Compassion Scale (SCS) [22], the
Relationship Scales Questionnaire (RSQ) [23], the Connor-
Davidson Resilience Scale (CDRS) [24], The Traumatic
Dissociation Scale (TDS) [25], and the Somatoform Dis-
sociation Questionnaire (SDQ) [26].
At the beginning of every therapy session, a five-item
empirically validated suicide checklist, the Suicide Be-
havior Monitoring Form (SBMF) [27], is completed by
the therapist. At the end of every other session (2, 4, 6,
8, and so on) study participants complete a brief (5-mi-
nute) assessment of PTSD symptoms (PCL-5) and the
TSI dissociation subscale to track change in symptoms
over the course of treatment. Treatment process is
assessed using the Working Alliance Inventory-12 item
(WAI-12) [28]. Satisfaction with the treatment and its
perceived usefulness as well as satisfaction with the clin-
ical environment (warmth, organization) is assessed using
a measure developed for this study and is completed at
Table 1 Assessment schedule by domain for study hypothesis
Measure Domain Enrollment Baseline Sessions
1-16
Mid-treatment
week 12
28-week
assessment
36-week
assessment
48-week
assessment
Informed consent X
Screen X
Primary outcome
CAPS PTSD Dx & Symptom Severity X X X X
Secondary outcomes
IIP Interpersonal problems X X X X X
DERS Emotion regulation X X X X X
GAF Functional status X X X X
Baseline
psychopathology
SCID I Axis I disorders X X X X
SCID-II Screen Axis II disorders X X
BSI General distress X X X X X
SF-36 Subjective health functioning X X X X
HSUF Recent and ongoing
health service utilization
X XXX
Treatment and
treatment process
PCL-5 PTSD self-report X Alternate
sessions
X XXX
TSI-Diss Dissociation self-report X Alternate
sessions
XX
WAI Therapeutic alliance Sessions 1 to 5 X
TES Satisfaction with treatment
and environment
X
BSI: Brief Symptom Inventory, CAPS: Clinician Administered PTSD Scale, DERS: Difficulties in Emotion Regulation Scales, GAF: Global Assessment of Functioning,
HSUF: Health Service Utilization Form, IIP: Inventory of Interpersonal Problems, PCL: 5 PTSD Checklist, SCID: Structured Clinical Interview for Diagnosis, TES:
Treatment Experience Scale, TSI: Trauma Symptom Inventory, WAI: Working Alliance Inventory.
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pists for each treatment case.
Enrollment
Enrollment involves a two-stage process. Potential candi-
dates are self-referred or referred by a clinician in the
service. The project coordinator at each site completes
an informed consent process with the potential candi-
date and a face-to-face screen to determine whether or
not the potential participant is willing to adhere to study
conditions, is likely to have PTSD and to meet other in-
clusion and exclusion criteria. If the basic criteria appear
to be satisfied, the project coordinator schedules a sec-
ond appointment to complete the baseline assessment
to confirm the diagnosis of PTSD and all other study
criteria. Any necessary contact with existing providers
occurs after the assessment to ensure that the project
coordinator has a complete mental health history, to
make certain that the other provider(s) are aware of
the potential participant’s interest in enrolling in the
study, and to ensure their understanding of the study
protocol. The candidates are contacted within 1 to
5 days of the baseline assessment regarding their eligi-
bility for the study. Patients will receive payment for
completing baseline, 28-, 36-, and 48-week assessments
to cover costs of travel and other expenses (for ex-
ample, childcare).
Randomization
Eligible participants are randomly assigned to either
SNT or TAU. The study manager located at the coordin-
ating site provides each clinical site with the treatment
assignment upon a phone or text request by the project
coordinator. Participants are randomized to STAIR
Narrative Therapy or TAU in blocks of random size (2,
4, or 6) stratified by site. The randomization lists were
generated by ‘R’, an open source statistical program. The
treatment condition to which the participant is random-
ized is not revealed until she arrives at her first
treatment session. Thus attrition that occurs between ac-
ceptance for treatment and the first session cannot be
attributed to treatment assignment. The interval be-
tween completion of baseline assessment and first treat-
ment session is expected to be no more than 2 weeks. If
circumstances occur such that attendance at first session
occurs more than 4 weeks after completion of assess-
ment, the CAPS is re-administered. The outcome asses-
sors are located at the coordinating site and are blind to
the participants’ treatment condition. Unblinding con-
cerning treatment allocation is permissible if a study
participant experiences a serious adverse event and
reporting to the Data Monitoring Committee (DMC)
and the funder (NIMH) is required.
Treatment
STAIR Narrative Therapy (SNT)
SNT is a 16 session manualized treatment that is deliv-
ered in 60-minute weekly sessions in an individual for-
mat. The STAIR module focuses on resolving problems
in daily living through skills training in emotion manage-
ment and interpersonal functioning. The first four ses-
sions focus on increasing emotion regulation skills
including awareness of feelings, self-soothing exercises,
and distress tolerance. The second four sessions focus
on development of interpersonal skills and include emo-
tion management in the context of social/interpersonal
interactions, exploration and revision of maladaptive
interpersonal schemas, effective assertiveness, and in-
creased flexibility in interpersonal expectations and be-
haviors depending on context. Narrative Therapy is a
modified version of prolonged exposure. Two interven-
tions have been added to standard prolonged exposure
approaches: (1) ‘grounding’ exercises immediately after
exposure, and (2) cognitive reappraisal of the meaning of
the trauma, with a focus on interpersonal schemas. Ex-
pectations about relationships derived from the trauma
narrative are identified and validated, and then con-
trasted with alternative beliefs or ‘working models’, de-
veloped during STAIR that may be more adaptive for
current relationships. Repeated practice of interpersonal
skills between sessions functions as a skills-building
intervention as well as a form of in-vivo exposure re-
garding generalized fears concerning social interactions
and relational engagement [7].
SNT is flexibly applied following the guidelines estab-
lished in a previous study that evaluated the effects of
flexible delivery of the treatment [29]. The study found
outcomes to be equivalent to those obtained in a previ-
ous trial that required strict adherence to the protocol
[7]. In the current study, treatment can range from 16 to
24 sessions. The type and number of sessions are deter-
mined by the clinician, whose decisions are guided by
the needs of the individual patient. The study protocol
allows (a) skipping protocol sessions, (b) repeating ses-
sions, and (c) having non-protocol sessions. There are
constraints, such that each of the three components of
the treatment has a minimum number of sessions as fol-
lows: (1) three sessions of skills training in emotion
regulation; (2) four sessions of skills training in interper-
sonal effectiveness; (3) five sessions of narrative work;
and (4) two sessions that bookend the treatment, namely
the introduction to treatment and termination sessions.
This formula requires that a total of 14 sessions are
committed to a particular set of interventions. The clin-
ician can adhere very closely to the minimum require-
ments and use only two additional sessions to deviate
from the protocol (for a total of 16) or can deviate rather
substantially with the addition of 10 sessions (for a total
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regulation, interpersonal, narrative, or non-protocol ses-
sions, as determined by the clinician.
The selection of TAU as a comparator
The comparator in this study is TAU as it is delivered in
each of the community sites. Substantial consideration
went into making this decision. Some clinical trials use a
standardized TAU and develop manuals of supportive
counseling or generic problem-centered therapy for im-
plementation [30,31], while others have a TAU condition
in which the treatment implemented is that which is
typically provided in the setting [32,33]. The benefit of
standardizing TAU is that it creates a control condition
that is well defined and constant across sites. This re-
duces the heterogeneity of the outcomes from the TAU
condition, thus increasing the power of the tests for the
differences between conditions (for a given sample size),
and internal validity. However, external validity is lim-
ited. That is, the comparison does not allow an assess-
ment of a question of clinical interest and practical
import, which is whether SNT is more effective than
current practice. Standardized TAU is not necessarily
like the treatments used by community providers, but
rather is a constructed treatment approximating what
therapists actually do in practice. Accordingly, if the re-
sults indicated that SNT was more effective than a stan-
dardized TAU, the findings might be dismissed by
community organizations as having little relevance to
their practice. The weakness of a design that uses TAU
as it naturally occurs in a clinic, particularly in a multi-
site study, is that there is likely to be wide variation in
TAU from site to site, raising the concern that between-
site variability will reduce the power of the study to de-
tect clinically meaningful differences between the treat-
ments. In addition, the nature of TAU often remains
unidentified, as content is rarely monitored.
We decided to use TAU as it naturally occurs in
clinics, in order to be able to determine the ‘real world’
value of SNT and the study sample size was selected to
account for the extra variance due to TAU heterogeneity.
Meta-analyses of multisite studies indicate that the vari-
ability in outcomes between sites tends to be smaller
than the within-site differences between the treatments
[34]. We identified the range of effect sizes that have
been found for naturally occurring TAU, based on those
available in the few PTSD and the more numerous
PTSD/SUD studies that have used community TAU as a
comparator. This range was used to guide our power
calculations described later in this paper (see Statistical
Analysis section). In addition, we developed a manual,
itemizing interventions from a range of other treatment
modalities (psychodynamic, cognitive behavioral, sup-
portive, mindfulness/meditation), that would be used to
evaluate the content of TAU. These data will help to
characterize TAU at each site, and will also allow some
analyses about interventions within TAU that are associ-
ated with good outcome.
Additional treatment
Participants may stay on medication, attend self-help
groups, and receive treatment for mental health prob-
lems other than PTSD. The presence of concurrent psy-
chotherapy is unacceptable only if the treatment is a
PTSD treatment or a trauma-focused intervention. Par-
ticipants who develop problems requiring additional in-
patient or outpatient treatment may receive additional
treatment as determined by the therapist, the site par-
ticipating investigator, and the supervisor of the treat-
ment condition to which the participant has been
assigned. The amount and type of additional treatment
is monitored and documented across all sites using a
standardized form (that is, Health Utilization Form
(HSUF)). After completing the study treatment, partici-
pants may seek additional treatment outside the study as
clinically indicated and this is similarly monitored with
the HSUF in the follow-up assessments at 36 and
48 weeks.
Discontinuation
Treatment is discontinued for participants who become
actively suicidal or homicidal, engage in an uncontrolled
episode of alcohol or drug abuse that requires immediate
treatment, or requires inpatient psychiatric treatment.
Participants may also be discontinued from the study if
they resume or initiate a relationship in which they are
being physically or sexually abused. Treatment can also
be discontinued when further study treatment is deter-
mined by the treating clinician and supervisor to be clin-
ically inappropriate.
Treatment is also discontinued when participants fail
to attend three consecutive therapy sessions or a total of
six sessions throughout the course of the treatment,
without a reason judged by their therapist or site team
to be acceptable. For intent-to-treat (ITT) purposes, all
participants, including those who are terminated early,
are assessed at 28 weeks, 36 weeks, and 48 weeks after
randomization. Participants who are discontinued from
the study for any reason are referred to more appropri-
ate types of treatment as indicated.
Therapist selection, training, and supervision
Potential therapists for the study are identified by the
site PI in conjunction with the study PI. Therapists are
required to have a master’s or doctoral degree in clinical
or counseling psychology, social work or psychiatric
nursing, or a medical degree with specialization in
psychiatry. Therapists at each site are assigned to either
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with the option of obtaining training in SNT at the end
of a 2-year commitment as a TAU therapist. It is ex-
pected that most therapists would be women. However,
male therapists may participate based on clinic culture
and staffing patterns. We will explore the potential rela-
tionship between degree, gender, years of experience,
and theoretical orientation to implementation patterns
and outcome.
Training in SNT includes reading the workbook [9],
which describes the theory and principles of treatment,
observing a videotape of a ‘gold standard’ 16-session
treatment that follows the study SNT treatment manual,
and completing a training case. The training case re-
quires completing all eight sessions of skills training and
at least four sessions of exposure. The case sessions are
audiotaped and supervised session by session. The test
case is rated for adherence by two trained adherence
raters who report deviation from protocol to the super-
visor. The SNT adherence manual rates adherence to
core interventions as a categorical assessment (yes or
no). Successful completion of a training case is defined
as achieving a 75% adherence rating on a minimum of
12 sessions which include sessions from the emotion
regulation, interpersonal skills, and narrative modules. If
the therapist does not reach this level of adherence, the
therapist completes additional mock intervention ses-
sions with the supervisor until she meets the criteria of
75% adherence. If adherence is less than 50%, the ther-
apist will complete a second case. SNT supervision oc-
curs weekly at each site with both the site PI and one of
the SNT trainers (Drs. Cloitre and Jackson).
Fidelity monitoring
SNT and TAU treatment sessions are audiotaped and
sent to the coordinating site for coding. SNT sessions
are coded for therapist adherence. TAU sessions are
coded to characterize their elements and to assess for
presence of specific interventions in SNT using an
adapted version of an established coding procedure, the
Hamburg Psychotherapy Process Scale (HaPPS-O) [35].
Coding of key therapeutic elements is completed for
psychodynamic, cognitive behavioral and supportive
therapy, mindfulness/meditation practices as well as the
specific core elements of SNT. Coding of SNT and TAU
will allow a comparison of the degree to which elements
in TAU may overlap with those of SNT.
SNT tapes are reviewed on a weekly basis by 10 PhD
students with a Masters degree in psychology and a
minimum of 2 years of clinical experience with public
sector patients. Training on adherence rating requires a
half-day review of the adherence rating protocols
followed by practice ratings of eight tapes (five SNT and
three TAU). For the SNT condition, two out of three
sessions (or 67% of cases) are rated. For the TAU condi-
tion, a total of three tapes per case is randomly sampled
(excluding first and last session). Each tape is assessed
by two raters. The PI (MC) reviews 10% of each rater’s
tapes to guard against rater drift. The PI also meets
quarterly (or more frequently if needed) with raters to
maintain consistent quality of ratings and to resolve
identified discrepancies.
Use of technology to enhance resources and support
sustainability
There is accumulating evidence that web-based technol-
ogy is an efficient and effective method of supporting
clinical training [36]. We will incorporate a web-based
platform to (1) make standard clinical materials readily
available and easily downloadable during the treatment
trial itself and (2) provide a platform through which
treatment materials can be managed and clinical net-
works across the sites can be maintained and expanded
after the study is completed. Reactions to the use of the
web, including perceptions of its impact on sense of pro-
fessional support, self-efficacy, and work satisfaction, as
well as its potential as a tool for enhancing dissemin-
ation of evidence-based treatment will be obtained
through two sets of focus group interviews with clini-
cians; one will be conducted around the half-way mark
of the trial and the other at the end of the trial.
Data management
The data management site will provide paper case report
forms (CRFs) for the collection of all data required by
the study. Data will be collected at the study site on
paper and entered by the project coordinator on a daily
basis to computerized user-friendly electronic version of
the forms with a backend process that will identify miss-
ing, illogical, out of range, and inconsistent values for
each data element. The data will be reviewed for com-
pleteness, timeliness, and accuracy on a nightly basis. If
any errors are detected, an automatic electronic message
will flag the error for correction. Personnel from the
Data Management site will be available for consultation
if needed to facilitate the correction. When no further
errors are detected, the data management site will ‘lock’
the study data from further modification. No personal
identifying information is included in the dataset. Ori-
ginal data files with identifying information are double-
locked (that is, kept in locked cabinets and locked
rooms) at each of the clinical sites.
Statistical analysis
Sample size determination
The sample size was determined based on the primary
hypotheses regarding superiority of SNT compared to
TAU immediately post-treatment (at week 28 post-
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during follow up (from 28 to 36 and 48 weeks post-
randomization). Reviews of the literature indicated that
the pre-post effects with STN were consistently large
with Cohen’s d effect size greater than 0.80 [7,8,29]. In
contrast, a review of the relatively small PTSD literature
that has used TAU as a comparator and the somewhat
larger PTSD/SUD literature revealed that effect sizes as-
sociated with TAU ranged widely from 0.3 to 1.2 [32,33].
The sample size was determined to allow 80% power of
a two-sided test with level of significance α =0.05 to de-
tect (a) differences immediately post treatment with re-
spect mean CAPS of size Cohen’s d=0.35; and (b)
differences in the course of symptoms during follow up
that result in a difference of size Cohen’s d= 0.8 at 6-
month follow-up. The necessary sample size depends on
the variation in the TAU effects between sites, the clus-
tering due to therapist (which reduced the effective
sample size by a magnitude that depended on the correl-
ation between outcomes of participants treated by the
same therapist), the clustering due to site, (which re-
duces the variance of the difference between treatments,
akin to pairwise t-test being more efficient than 2-
sample t-test) and the correlation between the three
repeated observations on a patients ranging from. We
project 20% dropout prior to the first treatment session
and overall 30% missing post-randomization data. Con-
sidering ranges of possible values of these factors and
selecting most conservative likely combination of them
determined that a total n = 352 patients from a mini-
mum of four sites would be necessary. This sample size
also allows sufficient power to detect difference of 20%
in the remission rates at 28 weeks and an increase of this
difference during follow-up by 25%. Regarding the hy-
potheses concerning the secondary outcomes, the study
provided sufficient power to detect effects similar to
those for symptoms severity measured by CAPS as the
secondary measures are continuous.
Hypotheses testing regarding SNT as compared to TAU
The primary hypothesis of the study is that SNT will be
more effective than TAU for the treatment of PTSD, as
well as for frequently co-occurring problems in emotion
regulation, relationships, and general functioning. All
analyses will be on the intent-to-treatment (ITT) sample
with imputation for missing data. The intent-to-treat
sample is defined as all randomized participants who at-
tend at least the first therapy session at which they are
notified about their treatment assignment. Testing of all
hypotheses (including those concerning differences at a
particular time point), will be based on models for longi-
tudinal data [37]. Continuous outcomes such as severity
of PTSD symptoms, emotion regulation problems, and
interpersonal problems will be modeled with linear
mixed effects model (MEM), while dichotomous out-
comes, such as PTSD remission, will be modeled using
generalized linear mixed effects model (GMEM).
Given the small number of sites, the ability to estimate
the site variability with sufficient precision is limited. For
this reason, the site and site-by-treatment and site-by-
treatment-by-time interaction effects will be modeled as
fixed effects and the variation between sites will be ex-
amined informally. The main effect of site will be in-
cluded in all models whether or not it is significant. In
order to protect against erroneous omission of import-
ant site effects, the statistical significance of the interac-
tions involving site and treatment will be judged at level
α =0.15, and the site-specific treatment effects will be
estimated with 95% CIs, rather than considered nil when
not reaching statistical significance at α =0.05 level.
Exploratory analyses regarding SNT patterns of
implementation
One aim of the study highly relevant to the concerns of
implementation research, per se, is our plan to assess the
potential benefits and/or drawbacks of allowing flexible
delivery of the protocol. Flexible implementation variables
will follow those used in Levitt et al. [29] and will include:
number of sessions (ranging from 16 to 24), different
types of flexible adaptations (repetitions, skips of key in-
terventions) for the treatment in its entirety, as well as the
number of sessions and occurrence of each type of adapta-
tion within each intervention component (emotion regula-
tion skills, interpersonal skills, and narrative work).
Each participant in the SNT condition will have values
for these variables defining how the treatment was im-
plemented for her. We plan to identify patterns of im-
plementation associated with patient outcomes for
patients at different levels of baseline severity. We will
categorize patients according to level of baseline severity
defined in various ways (PTSD severity, GAF score,
number of co-morbidities). For each of these catego-
rization schemes, patterns of implementation associated
with outcome will be identified: excellent outcome
(those achieving remission), good outcome (improve-
ment but not remission), and poor outcome (no change
or worsening). In addition to traditional regression
models, recursive partitioning methods [38,39] will be
utilized, allowing the identification of implementation
patterns (groupings of implementation variables) as they
are associated with baseline severity and outcome, and
leading to the identification of optimal implementation
patterns for given baseline characteristics.
Qualitative interviews regarding contexual characteristics
We will introduce and explore the influence of contextual
variables including clinician characteristics (for example,
age, gender, professional training, years of experience) and
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patient perception of organizational support and organi-
zational resources (support staff, material resources) for
both SNTand TAU at the end of the treatment. All partic-
ipants will assess their treatment experience at the end of
their treatment and, in parallel, the clinicians will evaluate
their perception of organizational support and resources
for each particular patient. In addition, focus groups for
clinicians and for study administrative staff will be con-
ducted twice during the life of the study, once at the mid-
point of the study’s treatment trial (when approximately
half of the participants have completed the treatment) and
the second near the end of the treatment trial.
Discussion
This study is designed to evaluate the implementation of
an evidence-based treatment for PTSD in public sector
community settings with community clinicians. To date,
there have been no large-scale clinical trials of an
evidence-based PTSD treatment in the general commu-
nity. While PTSD clinical trials have been completed in
the VA service system, its specific veteran population as
well as the policies, structures, and processes that guide
implementation efforts in the VA may not generalize to
public sector community mental health settings. This
study, with its large sample and multi-site design is ex-
pected to yield evidence regarding the effectiveness of
SNT relative to usual care on PTSD and range of co-
morbidities, as well as secondary outcomes such as
health status and health service utilization in a chronic-
ally traumatized and impoverished patient population.
The study will also contribute to knowledge in imple-
mentation science. Specifically, the study will test a flex-
ible implementation strategy of the study treatment, in
which the therapist and the patient pair will select a subset
of interventions within the three core intervention mod-
ules (emotion management, interpersonal/social skills,
and narrative therapy) based on the patients’ needs and
preferences. The study therefore emphasizes a patient-
centered approach to the delivery of an evidence-based
treatment and may be the first to provide data regarding
the outcomes of treatment as they relate to specific pat-
terns of intervention use. The sample size, along with ap-
propriate use of state-of-the-art statistical techniques, will
allow us to identify patterns of implementation (variations
in selected interventions) associated with both good and
bad outcomes, and in particular, as they relate to different
levels of severity in psychiatric illness.
The study will more broadly contribute to implemen-
tation science in that both qualitative and quantitative
data will be obtained from several different types of
stakeholders in the public sector setting including pa-
tients, clinicians, and administrators concerning factors
that impeded and facilitated the implementation process.
This information will contribute to the evidence base
seeking to identify factors and strategies that support
and facilitate change in community mental health sys-
tems. The delivery of psychotherapy in poverty level set-
tings has special challenges. In such settings, experiences
of chronic and repeated violence, unemployment, lim-
ited material resources (for example, funds for transpor-
tation, rent, and childcare), and variable access to
healthcare create a backdrop of chronic stress and un-
predictability that adversely affects the ability of the
mental health system to serve patients effectively. While
these circumstances are highly challenging, they are un-
fortunately quite common in public sector settings. This
study is important in that it will provide information
about the process and outcomes associated with intro-
ducing innovations into the context of a highly stressed
type of mental health system.
Trial status
Currently screening and recruiting for participants.
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